验证非溃疡性T1b黑色素瘤前哨淋巴结活检选择标准
本研究利用2022年美国国家癌症数据库,验证了基于核分裂率、年龄和Breslow厚度的算法在非溃疡性T1b黑色素瘤患者中筛选前哨淋巴结活检低风险人群的效果。结果显示,核分裂率<1/mm2的患者SLN阳性率为3.9%,据此可使38%的患者免于活检;该算法比澳大利亚黑色素瘤研究所的列线图能避免更多活检(39% vs 28%)。
要点
- 核分裂率<1/mm2的非溃疡性T1b患者SLN阳性率仅3.9%(95%CI 3.5-4.4%)。
- 核分裂率≥1/mm2且厚度<1.0mm且年龄>56岁的低风险组SLN阳性率达5.7%(95%CI 5.0-6.4%),超过5%阈值。
- 采用核分裂率<1/mm2标准可使38%的非溃疡性T1b患者避免SLN活检。
核心结论
- 约三分之一非溃疡性T1b黑色素瘤患者SLN阳性风险低,核分裂率联合年龄可作为选择SLN活检的决策辅助工具。
研究设计与样本
- 回顾性队列研究,使用2022年美国国家癌症数据库公共使用文件,纳入2016-2022年经SLN活检分期的临床淋巴结阴性非溃疡性T1b黑色素瘤患者,共18957例。
主要发现
- 核分裂率<1/mm2的患者SLN阳性率为3.9%(95%CI 3.5-4.4%);核分裂率≥1/mm2且厚度<1.0mm且年龄>56岁的患者SLN阳性率为5.7%(95%CI 5.0-6.4%)。
- 以核分裂率<1/mm2为标准,38%的非溃疡性T1b患者可避免SLN活检。
- 本算法可使39%患者避免SLN活检,而澳大利亚黑色素瘤研究所列线图仅为28%。
- 核分裂率=0时,年龄≤42岁患者SLN阳性率为7.0%(95%CI 5.2-9.1%),年龄≤56岁患者为5.4%(95%CI 4.3-6.6%),提示年轻患者应考虑SLN活检。
临床怎么用
- 在无法计算澳大利亚黑色素瘤研究所列线图参数时,可采用核分裂率联合年龄作为推荐SLN活检的决策辅助。
- 对核分裂率<1/mm2的非溃疡性T1b患者,可考虑免除SLN活检。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Controversy exists regarding the overutilization of sentinel lymph node biopsy for nonulcerated T1b melanomas. We previously proposed an algorithm based on mitotic rate, age, and Breslow thickness that suggested that over half of nonulcerated T1b patients could forgo sentinel lymph node biopsy. We sought to validate this model and compare it with the Melanoma Institute Australia's nomogram. METHODS: The 2022 National Cancer Database Public Use File was used to identify clinically node-negative melanoma patients with nonulcerated T1b melanomas staged by sentinel lymph node biopsy from 2016 to 2022. The sentinel lymph node positivity rates for our previously described low-risk groups (mitotic rate = 0 mm2 or mitotic rate ≥1/mm2 + thickness <1.0 + age >56) were calculated. The Melanoma Institute Australia's nomogram was used to calculate predicted sentinel lymph node positivity for patients with pathologically complete records. RESULTS: We identified 18,957 patients with nonulcerated T1b melanomas who underwent sentinel lymph node biopsy. A mitotic rate of <1/mm2 had a low risk of a positive sentinel lymph node (3.9%; 95% confidence interval, 3.5-4.4%). The other previously proposed low-risk group had a sentinel lymph node-positive rate exceeding the >5% threshold (5.7%; 5.0-6.4%). Using a mitotic rate <1/mm2 as a criterion, 38% of T1b nonulcerated patients could avoid sentinel lymph node biopsy. More patients would avoid sentinel lymph node biopsy with our algorithm versus the Melanoma Institute Australia's nomogram (39% vs 28%). For those with mitotic rate = 0, age cutoffs of ≤42 (sentinel lymph node + rate 7.0%, 5.2-9.1%) or ≤56 (sentinel lymph node + rate 5.4%, 4.3-6.6%) identified younger patients for whom sentinel lymph node biopsy should be considered. CONCLUSION: One-third of patients with nonulcerated T1b melanomas have a low predicted risk of a positive sentinel lymph node. When parameters are not available to calculate the Melanoma Institute Australia's nomogram, mitotic rate in conjunction with age is a suitable decision aid for recommending sentinel lymph node biopsy.
引用
- Quinn L P, Walter D, Kyle R S, et al. Validation of previously proposed criteria for selecting nonulcerated T1b melanoma patients for sentinel lymph node biopsy. Surgery. 2026. PMID: 42335728. doi:10.1016/j.surg.2026.110344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。